Antioxidant Nanoparticle Reduces Pain Peptides Substance P and CGRP in Disc-Related Nerve Pain

What the researchers found

In a mouse radiculopathy model, fullerol at 10 or 100 μM counteracted pain sensitization and inflammatory responses when disc material was pretreated before implantation. While macrophage infiltration (IBA1+) was similar across groups, IL-1β and IL-6 expression was decreased in the fullerol-treated group.

In dorsal root ganglion (DRG) explant cultures treated with TNF-α, fullerol significantly reversed the increased expression of IL-1β, NLRP3, and caspase 1, identifying the NLRP3 inflammasome as a key target. Critically, fullerol also decreased expression of the pain neuropeptides substance P and CGRP in cultured DRGs, explaining its analgesic effect.

Why it matters

Radiculopathy from disc degeneration is a major cause of chronic pain with limited treatment options — NSAIDs have side effects and opioids carry addiction risk. Fullerol targets the pain at multiple levels: reducing inflammation via the NLRP3 inflammasome and lowering pain-amplifying neuropeptides substance P and CGRP. This multi-target approach could offer advantages over single-pathway pain drugs.

How the study worked

The study used two complementary models: a mouse radiculopathy model where disc material was bathed in fullerol (10 or 100 μM) before being surgically implanted near nerve roots, and an ex vivo dorsal root ganglion explant culture stimulated with TNF-α. Pain behavior was assessed in vivo, and inflammatory and neuropeptide markers were measured by immunohistochemistry and molecular analysis.

What this study cannot tell us

This is a preclinical study in mice and cell culture with no human data. The fullerol was applied as a pretreatment to disc material before implantation, which doesn't mirror how a drug would be delivered to patients with existing disc disease. Specific dosing for clinical use and long-term safety of nanoparticle fullerol administration are not addressed. The mechanism by which fullerol reaches and acts on DRG neurons in vivo needs clarification.

How to read the evidence

This is a preclinical study using a mouse radiculopathy model and ex vivo nerve tissue cultures. It provides mechanistic evidence for fullerol's analgesic effects but is far from clinical application.

When this study was published

Published in 2017, this study is somewhat older but represents foundational work on nanoparticle approaches to neuropeptide-mediated pain. More recent studies may have built on these findings.

The bigger picture

This study connects nanotechnology with pain neurobiology, showing that a carbon nanoparticle can modulate neuropeptide signaling pathways involved in chronic pain. The NLRP3 inflammasome has emerged as a major target in pain and inflammatory research, and the additional effect on CGRP is notable given the success of CGRP-targeting drugs in migraine. This work suggests nanoparticle approaches could become part of pain management strategies.

Questions still open

• Could fullerol be delivered locally to damaged discs in humans, and by what method?
• How does fullerol's effect on CGRP compare to that of CGRP-blocking drugs like gepants or monoclonal antibodies?
• What is the long-term safety profile of carbon nanoparticle fullerol in nervous tissue?

Common questions

Read the original research

Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides.

Nanomedicine : nanotechnology, biology, and medicine, 13(6), 2049-2059

Citation

Jin, Li; Ding, Mengmeng; Oklopcic, Azra; Aghdasi, Bayan; Xiao, Li; Li, Ziyi; Jevtovic-Todorovic, Vesna; Li, Xudong. (2017). Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides.. Nanomedicine : nanotechnology, biology, and medicine, 13(6), 2049-2059. https://doi.org/10.1016/j.nano.2017.03.015